Advanced CSCC: What to Do When Surgery Just Isn’t Going to Cut It: A Care Team Forum℠

Program Overview

The goal of this activity is to provide education about immunotherapy in advanced CSCC that is not amenable to surgery or radiotherapy.

Credit Expired

Target Audience

This activity is intended for oncology, dermatology, and dermato-oncology clinicians who manage patients with cutaneous squamous cell carcinoma (CSCC). The goal of this activity is to provide education about immunotherapy in advanced CSCC that is not amenable to surgery or radiotherapy.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Effectively identify CSCC and assess risk of developing advanced disease
Delineate the safety and efficacy of immunotherapeutic agents for CSCC
Effectively manage immune-mediated adverse reactions associated with the mechanism of action of checkpoint inhibitors
Select therapy for individual patients according to current evidence and guidelines, offering clinical trial enrollment where appropriate

Activity Faculty

Badri Modi, MD (Chair)

Assistant Clinical Professor
Division of Dermatology
City of Hope
Duarte, California, United States

Irene Brana, MD, PhD

Clinical Investigator, Molecular Therapeutic Research Unit and ENT Unit
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Victor Moreno, MD, PhD

Director, Clinical Research Phase 1 Clinical Trial Unit
START Madrid-FJD
Hospital Fundación Jiménez Díaz
Madrid, Spain

Featured RMEI CE Activities – Earn CE Credit(s)

A Non-CME Educational Program during the 2025 AAAAI/WAO Joint Congress: Expert Panel Discussion Featuring a Patient

A Violent Graft in a Vulnerable Host: The Future of aGvHD Management: A Care Team Forum®

1.5 CE Credit(s)

Rapid Recognition and Management of T-Cell Therapy-Related Toxicities in B-Cell Lymphomas: Crucial Updates for the Emergency Department

1.0 CE Credit(s)

Privacy | Terms of Use